Abbott Launches US Pivotal Trial Of TriClip Transcatheter Tricuspid Valve Repair System

 
• By Reed Miller

The 700-patient TRILUMINATE Pivotal will compare Abbott’s TriClip transcatheter tricuspid valve repair device to medical therapy alone. TriClip is a tricuspid version of the company’s successful MitraClip transcatheter mitral valve repair device.

BEIJING, CHINA- JULY 15, 2017: Abbott sign; Abbott Laboratories, founded in 1888, is a health care company that serves worldwide. It has more than 20 billon USD in revenue last year. - Image
• Source: shutterstock.com

More from Clinical Trials

More from R&D